USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 300 [iu] in 1 ml

USA - engelsk - NLM (National Library of Medicine)

baxalta incorporated - coagulation factor ix human (unii: 6u90y1795t) (coagulation factor ix human - unii:6u90y1795t) - coagulation factor ix human 30 [iu] in 1 ml

Den europeiske union - engelsk - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - eftrenonacog alfa - hemophilia b - vitamin k and other hemostatics, blood coagulation factors - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - eftrenonacog alfa, quantity: 4000 iu - drug delivery system - excipient ingredients: - alprolix is a long-acting anti-haemophilic factor (recombinant) indicated in adults and children with haemophilia b (congenital factor ix deficiency) for: - control and prevention of bleeding episodes - routine prophylaxis to prevent or reduce the frequency of bleeding episodes - perioperative management (surgical prophylaxis)

Israel - engelsk - Ministry of Health

kamada ltd, israel - factor ix - powder for solution for injection - factor ix 1000 iu/vial - coagulation factor ix, ii, vii and x in combination - coagulation factor ix, ii, vii and x in combination - treatment and prophylaxis of bleeding in patients with haemophilia b ( congenital factor ix deficiency).

Den europeiske union - engelsk - EMA (European Medicines Agency)

sanquin plasma products b.v. - human coagulation factor ix - hemophilia b - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor ix deficiency).

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 1000 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - factor ix, quantity: 500 iu - injection, diluent for - excipient ingredients: water for injections - monofix-vf is indicated for the treatment of haemorrhages, for use in surgery, and as prophylaxis in patients with haemophilia b. monofix-vf is not indicated for the treatment of factor ii, vii or x deficiencies because it does not contain therapeutic levels of these coagulation factors. monofix-vf is not indicated for the treatment of haemophilia a patients with factor viii inhibitors.

Canada - engelsk - Health Canada

csl behring canada inc - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) - kit - 250unit - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) 250unit - hemostatics

Canada - engelsk - Health Canada

csl behring canada inc - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) - kit - 500unit - coagulation factor ix (recombinant), albumin fusion protein (rix-fp) 500unit - hemostatics